This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Truist Securities Maintains Hold on Apogee Therapeutics, Raises Price Target to $135

Truist Securities analyst Danielle Brill maintains Apogee Therapeutics (NASDAQ:APGE) with a Hold and raises the price target from $81 to $135.

BTIG Downgrades Apogee Therapeutics to Neutral

BTIG analyst Julian Harrison downgrades Apogee Therapeutics (NASDAQ:APGE) from Buy to Neutral.

8-K filing — Apogee Therapeutics, Inc. (APGE)

Filed: 2026-08-11 AccNo: 0001140361-26-032231 Size: 167 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 5.07: Submission of Matters to a Vote of Security Holders

President Trump Say In A Social Media Post That The University Of Miami Shared Its 1994 Ibogaine Investigational New Drug Application With The Government, Which Will Help Accelerate Development As A Medical Treatment In The U.S.

CoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For Wednesday

Wall Street analysts change outlook on top names. HC Wainwright raises price target for Belite Bio, while B of A cuts Lumentum's target.

Deutsche Bank Downgrades AtaiBeckley to Hold, Lowers Price Target to $8

Deutsche Bank analyst David Hoang downgrades AtaiBeckley (NASDAQ:ATAI) from Buy to Hold and lowers the price target from $12 to $8.